↓ Skip to main content

Design of Diarylheptanoid Derivatives as Dual Inhibitors Against Class IIa Histone Deacetylase and β-amyloid Aggregation

Overview of attention for article published in Frontiers in Pharmacology, July 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Design of Diarylheptanoid Derivatives as Dual Inhibitors Against Class IIa Histone Deacetylase and β-amyloid Aggregation
Published in
Frontiers in Pharmacology, July 2018
DOI 10.3389/fphar.2018.00708
Pubmed ID
Authors

Liang-Chieh Chen, Hui-Ju Tseng, Chang-Yi Liu, Yun-Yi Huang, Cheng-Chung Yen, Jing-Ru Weng, Yeh-Lin Lu, Wen-Chi Hou, Tony E. Lin, I-Horng Pan, Kuo-Kuei Huang, Wei-Jan Huang, Kai-Cheng Hsu

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with multiple etiologies. Beta-amyloid (Aβ) self-aggregation and overexpression of class IIa histone deacetylases (HDACs) are strongly implicated with AD pathogenesis. In this study, a series of novel diarylheptanoid derivatives were designed, synthesized and evaluated for use as dual Aβ self-aggregation and class IIa HDAC inhibitors. Among these compounds, 4j, 5c, and 5e displayed effective inhibitions for Aβ self-aggregation, HDAC5 activity and HDAC7 activity with IC50 values of <10 μM. The compounds contain three common features: (1) a catechol or pyrogallol moiety, (2) a carbonyl linker and (3) an aromatic ring that can function as an HDAC cap and create hydrophobic interactions with Aβ1-42. Furthermore, compounds 4j, 5c, and 5e showed no significant cytotoxicity to human neuroblastoma SH-SY5Y cells and also exhibited neuroprotective effect against H2O2-induced toxicity. Overall, these promising in vitro data highlighted compounds 4j, 5c, and 5e as lead compounds that are worthy for further investigation.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 23%
Student > Ph. D. Student 3 23%
Lecturer > Senior Lecturer 1 8%
Student > Master 1 8%
Researcher 1 8%
Other 1 8%
Unknown 3 23%
Readers by discipline Count As %
Chemistry 4 31%
Biochemistry, Genetics and Molecular Biology 3 23%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Medicine and Dentistry 1 8%
Psychology 1 8%
Other 0 0%
Unknown 3 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2018.
All research outputs
#20,527,576
of 23,096,849 outputs
Outputs from Frontiers in Pharmacology
#10,331
of 16,453 outputs
Outputs of similar age
#287,394
of 327,914 outputs
Outputs of similar age from Frontiers in Pharmacology
#246
of 395 outputs
Altmetric has tracked 23,096,849 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,453 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,914 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 395 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.